13 April 2025 : Review article
Inclisiran in Cardiovascular Health: A Review of Mechanisms, Efficacy, and Future Prospects
Fanke Huang ABCDEFG 1, Qiuting Dai FG 1, Yilu Zhou F 1, Jing Guan F 1, Jingjing Wu F 1, Yanyan Dong F 1, Jianfeng Lv AG 1*DOI: 10.12659/MSM.946439
Med Sci Monit 2025; 31:e946439
Table 1 High-frequency keywords of inclisiran (top 18).
| Rank | Keyword | Frequency | Rank | Keyword | Frequency |
|---|---|---|---|---|---|
| 1 | Inclisiran | 161 (52.1%) | 10 | Family hypercholesterolemia | 52 (16.8%) |
| 2 | Efficacy | 87 (28.2%) | 11 | Stain therapy | 50 (16.2%) |
| 3 | Pcsk9 | 75 (24.3%) | 12 | Ezetimibe | 47 (15.2%) |
| 4 | Saftety | 74 (23.9%) | 13 | Pcsk9 inhibitors | 47 (15.2%) |
| 5 | Risk | 69 (22.3%) | 14 | Atherosclerosis | 47 (15.2%) |
| 6 | Ldl-cholesterol | 64 (20.7%) | 15 | Alirocumab | 45 (14.6%) |
| 7 | Bempedoic acid | 62 (20.1%) | 16 | Double-blind | 42 (13.6%) |
| 8 | Evolocumab | 55 (17.8%) | 17 | Cardiovascular-disease | 36 (11.7%) |
| 9 | Hypercholesterolemia | 55 (17.8%) | 18 | Metaanalysis | 32 (10.4%) |